Head to Head Contrast: EOM Pharmaceutical (OTCMKTS:IMUC) versus Akebia Therapeutics (NASDAQ:AKBA)

EOM Pharmaceutical (OTCMKTS:IMUC) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.

Earnings & Valuation

This table compares EOM Pharmaceutical and Akebia Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EOM Pharmaceutical	N/A	N/A	-$1.89 million	N/A	N/A
Akebia Therapeutics	$225.07 million	1.57	-$69.41 million	($0.07)	-19.07

EOM Pharmaceutical has higher earnings, but lower revenue than Akebia Therapeutics.

Analyst Recommendations

This is a breakdown of recent ratings for EOM Pharmaceutical and Akebia Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EOM Pharmaceutical	0	0	0	0	0.00
Akebia Therapeutics	1	1	5	1	2.75

Akebia Therapeutics has a consensus target price of $6.00, indicating a potential upside of 349.44%. Given Akebia Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than EOM Pharmaceutical.

Profitability

This table compares EOM Pharmaceutical and Akebia Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EOM Pharmaceutical	N/A	N/A	N/A
Akebia Therapeutics	-7.07%	-137.67%	-5.13%

Institutional & Insider Ownership

33.9% of Akebia Therapeutics shares are held by institutional investors. 3.3% of EOM Pharmaceutical shares are held by insiders. Comparatively, 3.0% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

EOM Pharmaceutical has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

About EOM Pharmaceutical

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.